{"id":"NCT00856583","sponsor":"H. Lundbeck A/S","briefTitle":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","officialTitle":"Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-07","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2009-03-06","resultsPosted":"2011-08-01","lastUpdate":"2011-08-19"},"enrollment":9809,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Sertindole","otherNames":["Serdolect"]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"Sertindole","type":"EXPERIMENTAL"},{"label":"Risperidone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.","primaryOutcome":{"measure":"Number of Participants With All-cause Mortality","timeFrame":"As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months","effectByArm":[{"arm":"Sertindole","deltaMin":64,"sd":null},{"arm":"Risperidone","deltaMin":61,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"},{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18384186","20384598","20926264","20820795","20732794"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":266,"n":4905},"commonTop":["Electrocardiogram QT prolonged"]}}